| 2026-05-30 03:31:20 |
statusModule.statusVerifiedDate: 2025-10 |
statusModule.statusVerifiedDate: 2026-05 |
| 2026-05-30 03:31:20 |
statusModule.lastUpdateSubmitDate: 2025-10-02 |
statusModule.lastUpdateSubmitDate: 2026-05-27 |
| 2026-05-30 03:31:20 |
statusModule.lastUpdatePostDateStruct.date: 2025-10-08 |
statusModule.lastUpdatePostDateStruct.date: 2026-05-29 |
| 2026-05-30 03:31:20 |
outcomesModule.primaryOutcomes.[3]measure: Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who achieve a response |
outcomesModule.primaryOutcomes.[3]measure: Feasibility of combination nivolumab and ipilimumab as assessed by number of participants who start standard of care within standard treatment window |
| 2026-05-30 03:31:20 |
outcomesModule.primaryOutcomes.[3]description: Number of participants who achieve a response (improved progression free survival). |
outcomesModule.primaryOutcomes.[3]description: Number of participants who start standard of care treatment within 8 week |
| 2026-05-30 03:31:20 |
outcomesModule.primaryOutcomes.[3]timeFrame: Up to 2 years |
outcomesModule.primaryOutcomes.[3]timeFrame: Up to 8 weeks |
| 2026-07-28 00:26:04 |
statusModule.statusVerifiedDate: 2026-05 |
statusModule.statusVerifiedDate: 2026-07 |
| 2026-07-28 00:26:04 |
statusModule.lastUpdateSubmitDate: 2026-05-27 |
statusModule.lastUpdateSubmitDate: 2026-07-09 |
| 2026-07-28 00:26:04 |
statusModule.lastUpdatePostDateStruct.date: 2026-05-29 |
statusModule.lastUpdatePostDateStruct.date: 2026-07-10 |